Solana (NASDAQ:HSDT) Announces Quarterly Earnings Results

Solana (NASDAQ:HSDT) posted its quarterly earnings data on Friday. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.36), FiscalAI reports. Solana had a negative return on equity of 67.57% and a negative net margin of 1,427.15%.The business had revenue of $2.53 million during the quarter, compared to analyst estimates of $3.50 million.

Here are the key takeaways from Solana’s conference call:

• Institutional infrastructure launched: Solana Company’s first validated cluster is operational in Tokyo, with approximately 500,000 SOL in committed third-party stake and validator-related revenue expected to begin in the third quarter.
• Staking performance remained strong: The company generated $2.5 million, or 31,200 SOL, in second-quarter staking revenue and achieved a 6.14% net annualized yield versus a network average of approximately 5.68%.
• Legacy-business transition advanced: The cash-consuming medical-device business was divested, while the company completed its acquisition of a Hong Kong regulated trust company on July 15 for $2 million to support its Asia-Pacific institutional strategy.
• GAAP losses remained substantial: The company reported a $30.3 million second-quarter net loss, including a $25.4 million realized loss on digital assets, while general and administrative expenses rose to $11.1 million, although management expects costs to decline as divestiture-related expenses end.
• Capital allocation will remain valuation-dependent: Solana Company repurchased $2.3 million of shares during the quarter while trading below net asset value, but management said future buybacks, SOL purchases, or business investment will depend on which option offers the greatest SOL-per-share accretion.

Solana Stock Performance

Shares of HSDT stock opened at $1.70 on Friday. Solana has a fifty-two week low of $1.19 and a fifty-two week high of $25.50. The firm has a market capitalization of $99.26 million, a P/E ratio of -0.06 and a beta of 1.01. The stock’s fifty day moving average is $1.67 and its two-hundred day moving average is $1.95.

Analysts Set New Price Targets

A number of brokerages have issued reports on HSDT. Wall Street Zen lowered shares of Solana from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Solana in a report on Friday, July 17th. Zacks Research upgraded shares of Solana to a “hold” rating in a research report on Monday, April 27th. Finally, B. Riley Financial assumed coverage on Solana in a research report on Thursday, April 23rd. They set a “buy” rating and a $3.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $3.50.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC purchased a new position in shares of Solana during the 4th quarter worth approximately $1,006,000. LPL Financial LLC increased its holdings in Solana by 120.1% in the fourth quarter. LPL Financial LLC now owns 382,255 shares of the company’s stock valued at $1,105,000 after buying an additional 208,558 shares during the last quarter. State Street Corp acquired a new stake in shares of Solana during the 4th quarter worth about $464,000. Cetera Investment Advisers acquired a new position in shares of Solana in the 4th quarter valued at $347,000. Finally, Marshall Wace LLP acquired a new stake in shares of Solana during the fourth quarter worth about $195,000. 18.63% of the stock is currently owned by institutional investors and hedge funds.

Solana Company Profile

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non?invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.